Harmony Management Patent-Cliff Exposure & CMS Drug Spending Portfolio

Harmony Management (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $250.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$250.5M
2024 Medicare Part D Spend$132.5M
2024 Medicaid Spend$118.1M
California HCAI SB 17 Filings4 WAC filings (max 22.5% 2-yr change)